Skip to main content
Log in

Weitere Erfolge der dualen HER2-Blockade

Further success for dual HER2 block

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25–32

    Article  PubMed  CAS  Google Scholar 

  2. Baselga J, Bradbury I, Eidtmann H et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633–640

    Article  PubMed  CAS  Google Scholar 

  3. Minckwitz G von, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804

    Article  Google Scholar 

Download references

Einhaltung der ethischen Richtlinien

Interessenkonflikt. D. Forstmeyer gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D. Forstmeyer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Forstmeyer, D. Weitere Erfolge der dualen HER2-Blockade. Onkologe 19, 1078–1079 (2013). https://doi.org/10.1007/s00761-013-2594-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-013-2594-x

Navigation